Skin-directed radiation therapy for cutaneous lymphoma: The Mayo Clinic experience - 11/02/20
Abstract |
Background |
Focal or total skin radiation therapy can be used to treat mild to refractory cutaneous T-cell lymphoma.
Objective |
To report the broad therapeutic benefit of radiation therapy for cutaneous T-cell lymphoma.
Methods |
Retrospective, single-institution review of outcomes for skin-directed radiation therapy.
Results |
Skin-directed radiation therapy showed a 99% response rate and 80% complete response rate after treatment regardless of involvement, severity, histopathologic subtype, dose, or fractionation. The overall in-field recurrence rate was 15%, and median time to recurrence was 296 days (range, 1-1884 days). Focal and hypofractionated regimens were similarly associated with disease response and rare toxicity. Short-term rates of secondary skin cancer after treatment were comparable to expected incidence in a patient population without radiation.
Limitations |
Large total number of treatments courses compared with overall number of patients. Heterogenous mix of treatment regimens (no standardization of dose or fraction number).
Conclusions |
Radiation therapy is a well-tolerated treatment option for properly selected patients with cutaneous T-cell lymphoma.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous T-cell lymphoma, radiation therapy
Abbreviations used : CI, CR, CTCL, HR, LCT, OR, RT, TSEBT
Plan
Funding sources: None. |
|
Conflicts of interest: None disclosed. |
Vol 82 - N° 3
P. 634-641 - mars 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?